Plasma levels of atrial and brain natriuretic peptides in apparently healthy subjects: Effects of sex, age, and hemoglobin concentration

International Journal of Cardiology

Volumn 228, Issue , 2017, Pages 599-604

  Hamada, Mareomi ^a   Shigematsu, Yuji ^b   Takezaki, Masayuki ^c   Ikeda, Shuntaro ^b   Ogimoto, Akiyoshi ^d  

^a the Former Industrial Doctor of Matsuyama Branch of Shikoku Electric Power Company   (Japan)

^b EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c DAIO PAPER CORPORATION   (Japan)

^d Uwajima City Hospital   (Japan)

Author keywords

Aging; ANP; BNP; Healthy subjects; Hemoglobin; Sex

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; HEMOGLOBIN; BIOLOGICAL MARKER;

ADULT; AGE; AGED; ARTICLE; FEMALE; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; THROMBOCYTE COUNT; ADOLESCENT; AGING; BLOOD; IMMUNORADIOMETRIC ASSAY; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGING; ATRIAL NATRIURETIC FACTOR; BIOMARKERS; FEMALE; HEALTHY VOLUNTEERS; HEMOGLOBINS; HUMANS; IMMUNORADIOMETRIC ASSAY; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; SEX FACTORS; YOUNG ADULT;

EID: 84996835545     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.11.197     Document Type: Article

References (28)

1. [1] Mukoyama, M., Nakao, K., Saito, Y., et al. Increased human brain natriuretic peptide in congestive heart failure. N. Engl. J. Med. 323 (1990), 757–758.
2. [2] Yasue, H., Yoshimura, M., Sumida, H., et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90 (1994), 195–203.
3. [3] Tsutamoto, T., Wada, A., Maeda, K., et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 96 (1997), 509–516.
4. [4] Maeda, K., Tsutamoto, T., Wada, A., et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J. Am. Coll. Cardiol. 36 (2000), 1587–1593.
5. [5] Jourdain, P., Jondeau, G., Funck, F., et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP multicenter study. J. Am. Coll. Cardiol. 49 (2007), 1733–1739.
6. [6] Omar, H.R., Guglin, M., Discharge BNP is a stronger predictor of 6-month mortality in acute heart failure compared with baseline BNP and admission- to-discharge percentage BNP reduction. Int. J. Cardiol, 2016, 10.1016/j.ijcard.2016.07.117.
7. [7] Niinuma, H., Nakamura, M., Hiramori, K., Plasma B-type natriuretic peptide in a multiphasic health screening program. Cardiology 90 (1998), 89–94.
8. [8] Nakamura, M., Endo, H., Nasu, M., Arakawa, N., Segawa, T., Hiramori, K., Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population. Heart 87 (2002), 131–135.
9. [9] Wang, T.J., Larson, M.G., Levy, D., et al. Plasma natriuretic levels and the risk of cardiovascular events and death. N. Engl. J. Med. 350 (2004), 655–663.
10. [10] Kawai, K., Yoshimura, M., Harada, M., et al. Determination of the B-type natriuretic peptide level as s criterion for abnormalities in Japanese individuals in routine clinical practice: the J-ABS multi-center study (Japan abnormal BNP standard). Intern. Med. 52 (2013), 171–177.
11. [11] Yasue, H., Yoshimura, M., Jougasaki, M., et al. Plasma levels of brain natoriuretic peptide in normal subjects and patients with chronic heart failure: measurements by immunoradiometric assay (IRMA). Horm. Clin. 41 (1993), 397–403 (in Japanese).
12. [12] Kawabe, H., Takeshita, E., Ohta, A., et al. Plasma BNP concentration of normal subjects in an annual medical check-up: measurements by immunoradiometric assay (IRMA). Horm. Clin. 45 (1997), 1179–1185 (in Japanese).
13. [13] Redfield, M.M., Rodeheffer, R.J., Jacobsen, S.J., Mahoney, D.W., Bailey, K.R., Burnett, J.C. Jr., Plasma brain natriuretic peptide concentration: impact of age and gender. J. Am. Coll. Cardiol. 40 (2002), 976–982.
14. [14] Segawa, T., Nakamura, M., Itai, K., Onoda, T., Okayama, A., Hiramori, K., Plasma B-type natriuretic peptide levels and risk factors for congestive heart failure in a Japanese general population. Int. Heart J. 46 (2005), 465–475.
15. [15] Wang, T.J., Larson, M.G., Levy, D., et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 109 (2004), 594–600.
16. [16] Sugisawa, T., Kishimoto, I., Makino, H., Miyamoto, Y., Yoshimasa, Y., Association of plasma B-type natriuretic peptide levels with obesity in a general urban Japanese population: the Suita study. Endocr. J. 57 (2010), 727–733.
17. [17] Madamanchi, C., Alhosaini, H., Sumida, A., Runge, M.S., Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure. Int. J. Cardiol. 176 (2014), 611–617.
18. [18] Marumoto, K., Hamada, M., Hiwada, K., Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischaemia induced by dynamic exercise in patients with angina pectoris. Clin. Sci. (Lond.) 88 (1995), 551–556.
19. [19] Marumoto, K., Hamada, M., Aburaya, M., Hiwada, K., Augmented secretion of atrial and brain natriuretic peptides during dynamic exercise in patients with old myocardial infarction. Jpn. Circ. J. 59 (1995), 715–724.
20. [20] Mӧllmann, H., Nef, H.M., Kostin, S., et al. Ischemia triggers BNP expression in the human myocardium independent from mechanical stress. Int. J. Cardiol. 143 (2010), 289–297.
21. [21] Czernin, J., Müller, P., Chan, S., et al. Influence of age and hemodynamics on myocardial blood flow and flow reserve. Circulation 88 (1993), 62–69.
22. [22] Sayama, H., Nakamura, Y., Saito, N., Kinoshita, M., Why is the concentration of plasma brain natriuretic peptide in elderly inpatients greater than normal?. Coron. Artery Dis. 10 (1999), 537–540.
23. [23] Lainscak, M., von Haehling, S., Anker, S.D., Natriuretic peptides and other biomarkers in chronic heart failure: from BNP, NT-proBNP, and MR-proANP to routine biochemical markers. Int. J. Cardiol. 132 (2009), 303–311.
24. [24] Wang, T.J., Larson, M.G., Keyes, M.J., et al. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation 115 (2007), 1345–1353.
25. [25] Mukoyama, M., Nakao, K., Hosoda, K., et al. Brain natriuretic peptide as a novel cardiac hormone in humans: evidence for exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J. Clin. Invest. 87 (1991), 1402–1412.
26. [26] Lang, C.C., Choy, A.M.J., Struthers, A.D., Atrial and brain natriuretic peptides: a dual natriuretic peptide system potentially involved in circulatory homeostasis. Clin. Sci. (Lond.) 83 (1992), 519–527.
27. [27] Nishikimi, T., Yoshihara, F., Morimoto, A., et al. Significance of measurements of plasma ANP and BNP levels in essential hypertensive subjects – as a diagnostic indicator of left ventricular hypertrophy. Shinzo 28 (1996), 197–202 (in Japanese).
28. [28] Hamada, M., Shigematsu, Y., Kawakami, H., et al. Increased plasma levels of adrenomedullin in patients with hypertrophic cardiomyopathy: its relation to endothelin-1, natriuretic peptides and noradrenaline. Clin. Sci. (Lond.) 94 (1998), 21–28.